Tianjin Medical University Cancer Institute And Hospital

This study tests whether adding a drug called iparomlimab after standard chemoradiation can help older adults (70+) with advanced esophageal cancer that cannot be removed by surgery. Iparomlimab boosts the immune system to fight cancer. The goal is to see if this approach improve…

This study tests whether adding the drug serplulimab to standard chemoradiotherapy after cervical cancer surgery can help prevent the cancer from returning. About 134 women with high-risk features will be randomly assigned to one of two treatment groups. The main goal is to see h…

This study tests a new treatment for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has spread to the brain and is causing symptoms. The treatment combines a targeted pill (osimertinib) with a precise form of whole-brain radiati…

This early-stage trial is testing a new cell therapy called GK01, given alone or with chemotherapy, in 15 people with advanced solid tumors like pancreatic or stomach cancer. The main goal is to check safety and how the body handles the treatment. Researchers will also look for s…

This study looks at two different treatments for people with a type of esophageal cancer that shrank after initial drug therapy. Half the participants will have surgery to remove the tumor, while the other half will get radiation and more chemo instead. The goal is to see if avoi…

This study is for people with a type of esophageal cancer that can be removed with surgery. Researchers are testing whether adding two drugs (serplulimab and nimotuzumab) to standard chemoradiation can improve results. About 46 participants will receive the combination treatment …

This study tests whether adding the drug serplulimab to standard chemoradiotherapy helps control locally advanced cervical cancer. About 216 women with untreated, advanced cervical cancer will take part. The main goal is to see if the combination delays cancer growth or improves …

This study tests a combination of immune cells grown from the patient's own tumor (L-TIL) plus an immunotherapy drug (tislelizumab) after lung cancer surgery. It is for people with stage II to IIIB non-small cell lung cancer who had chemo-immunotherapy before surgery but still ha…

This study tests whether women with certain aggressive breast cancers (triple negative or HR-/HER2+) can skip surgery if their tumors disappear completely after chemotherapy and radiation. About 200 participants will receive the combined treatment and be monitored for 5 years to …

This study is testing whether a combination of three drugs (irinotecan liposome, capecitabine, and enlansubemab) given with a short course of radiation before surgery can shrink or eliminate tumors in people with locally advanced rectal cancer. About 30 adults aged 18-75 with sta…

This study looks at how bacteria inside tumors might help predict whether a patient with digestive cancer will respond well to chemotherapy before surgery. Researchers will collect tumor samples from 90 adults with stomach, colon, pancreas, or esophageal cancer to study these bac…